Dr. Ramaswamy Govindan is the Director of the Section of Medical Oncology at Washington University School of Medicine in St Louis. Dr. Govindan has led several institutional and multi-center phase III studies in lung cancer over the past decade. He is the Principal Investigator for the NCI-funded ALCHEMIST trial to study the role of erlotinib in patients with early stage EGFR mutated lung cancer. He co-led the lung cancer working group for The Cancer Genome Atlas (TCGA) project and currently serves as the co-chair of the ALCHEMIST Genomics Working Group. He led the group that has recently discovered resistance mechanisms for chemotherapy in small cell lung cancer. Dr. Govindan is keen on translating genomic discoveries from the laboratory setting to the clinical setting to improve the outcomes of patients with lung cancer. Dr. Govindan has published over 350 peer-reviewed papers in scientific journals and has been awarded several grants from the NCI.